Conclusions
In summary, based on our findings, we think that the outlook on
developing and evaluating new drugs for pregnant women may not be
bright, unless there are appropriate policies and measures. However, the
results of this study are not too frustrating either: In China, there
are still studies conducted in pregnant women at a certain frequency by
sponsors and clinical institutions. More attention should be paid to the
use of marketed drugs in pregnant women and give priority to the study
on the PK of pregnant women.